NCT01544114 - A Safety Study of VIMOVO in Adolescents With Juvenile Idiopathic Arthritis (JIA) | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

April 30, 2012

Primary Completion Date

February 28, 2015

Study Completion Date

February 28, 2015

Conditions

Juvenile Idiopathic Arthritis (JIA)

Interventions

DRUG

VIMOVO 250/20

250 mg naproxen/20 mg esomeprazole magnesium oral tablet administered twice daily for up to 6 months

DRUG

VIMOVO 375/20

375 mg naproxen/20 mg esomeprazole magnesium oral tablet administered twice daily for up to 6 months

DRUG

VIMOVO 500/20

500 mg naproxen/20 mg esomeprazole magnesium oral tablet administered twice daily for up to 6 months

Trial Locations (17)

10021

Research Site, New York

11040

Research Site, New Hyde Park

11203

Research Site, Brooklyn

19134

Research Site, Philadelphia

20010

Research Site, Washington D.C.

22030

Research Site, Fairfax

30912

Research Site, Augusta

33407

Research Site, West Palm Beach

38119

Research Site, Memphis

43623

Research Site, Toledo

44195

Research Site, Cleveland

45229

Research Site, Cincinnati

60637

Research Site, Chicago

68114

Research Site, Omaha

72202

Research Site, Little Rock

80045

Research Site, Aurora

94143

Research Site, San Francisco